Objective: To develop a system for the molecular diagnosis of tuberculosis by polymerase chain reaction (PCR), constructing primers based on the difference in gene organization of the intergenic region of phospholipase C (plcB-plcC region), which differentiates Mycobacterium tuberculosis from other mycobacteria. Methods: A PCR product of the expected size (432 bp) was obtained from M. tuberculosis and M. africanum only. A total of 33 mycobacterial isolates and 273 clinical samples from patients suspected of having tuberculosis were examined.
Introduction
Fast and accurate diagnosis is an important element of global health measures to control tuberculosis (TB). Moreover, since 90% of TB cases occur in developing countries, (1) a cost-effective diagnostic tool for TB that could be routinely used would be of great benefit. A number of methods based on nucleic acid amplification, including polymerase chain reaction-restriction enzyme analysis (PCR-REA), (2) commercial DNA assays, (3) PCR-based sequencing technologies, (4) and, more recently, realtime PCR assays, (5) have been developed for use in the identification of mycobacteria. A shortcoming of the PCR-REA method is its inability to distinguish the small differences in band size between some species of mycobacteria, (2) whereas a major drawback of commercial assays is their high cost. In addition, it has been reported that a commercial direct amplification test designed for the in vitro diagnostic detection of Mycobacterium tuberculosis complex rRNA can produce false-positive results for M. tuberculosis in AIDS patients infected with M. kansasii or M. avium, as well as in HIV-negative patients with chronic lung disease caused by M. avium. (6) Another commercial test has such a low sensitivity for smear-negative specimens that the United States Food and Drug Administration has approved it only for direct detection of M. tuberculosis in acid-fast bacilli smear-positive respiratory specimens. (7, 8) In addition, the ligase chain reaction test has not demonstrated a sufficient degree of accuracy with smear-negative specimens to warrant its use on a routine basis. (9) Although the use of nucleic acid sequencing is highly accurate, it is labor-intensive and requires expensive equipment. Therefore, various laboratories use in-house methods for the detection of M. tuberculosis. These assays have a wide variety of nucleic acid targets, such as insertion sequence (IS)6110, ribosomal ribonucleic acid genes, 65-kDa antigen, and heat shock protein 65 gene. (8) In such in-house assays, IS6110 is probably the target most widely used in the molecular detection of M. tuberculosis. (7, 10) However, M. tuberculosis strains that do not contain IS6110 have been reported, (5, 11, 12) and IS6110 homologs have been found in M. fortuitum, M. avium-M. intracellulare complex, M. kansasii, M. xenopi, M. malmoense, and M. chelonei clinical isolates, (13, 14) as well as in M. bovis. (15) According to data from the Pan American Health Organization and World Health Organization, 7000 new cases of human TB caused by M. bovis are reported in South America each year. (16) Differentiation between M. tuberculosis and M. bovis is particularly important, since the latter is resistant to pyrazinamide, a drug commonly used in the treatment of TB. (17) However, current methodologies to distinguish between M. tuberculosis and M. bovis have been largely unsuccessful due to their lack of resolution, (18) as well as to the fact that skilled laboratory personnel and relatively expensive consumable reagents are required. (19, 20) Upon performing comparative hybridization experiments, eleven regions present in M. tuberculosis H37Rv were found to be absent from one or more virulent strains of M. bovis (21) ; among them, a cluster of three phospholipase C genes (plcA, plcB, and plcC ). PCR amplification was performed as follows: initial denaturation at 94 °C for 5 min; 35 cycles of denaturation at 94 °C for 30 s, annealing at 65 °C for 30 s, extension at 72 °C for 30 s; and a final extension step at 72 °C for 5 min. The PCR products were analyzed by agarose gel electrophoresis (2% w/v) and stained with ethidium bromide. The clinical samples were also amplified with specific primers for human β-globin gene GH20 and PC04 (22) in order to detect inhibitory samples.
Direct sequencing of PCR fragments was performed in a commercial laboratory (CATG, Porto Alegre, Brazil) using the ABI PRISM BigDye Terminator kit (PE Applied Biosystems, Foster City, CA, USA), and the output was analyzed with an ABI 3700 DNA sequencer. The PCR amplification primers were also used as sequencing primers, and at least a single base overlap from two directions for each was usually achieved. The FASTA program (23) was used to compare the amplified sequence with a DNA sequence from the GenBank database.
The collected data were analyzed using SPSS software (version 1.0 for Windows). Pearson's chisquare was used to assess relationships between categorical variables, and the data were interpreted using the Kappa table.
Results
In order to optimize the PCR, we tested amplifications with different concentrations of MgCl 2 (1.5-2.5 mM). The best amplification efficiency was achieved with MgCl 2 at a concentration of 2 mM. A strong, 432-bp product, without nonspecific fragments and without abundant primer dimers, was observed. A PCR product of the expected size was showed that there was a near-perfect concordance between the two tests. These results compare favorably with those compiled in a recent review of the literature. (8) However, the mtp40 sequence has been shown to be absent from a number of M. tuberculosis strains. (18, 25) Interestingly, the mtp40 sequence has been shown to be part of the plcA gene. (25) In the present study, we used primers flanking the junction of the 3' end of the plcB gene and the 5' end of the plcC gene. In addition, our attempts to amplify a DNA fragment comprising the 3' end of the plcA gene, the intergenic region, as well as one comprising the 5' end of the plcB gene, failed (data not shown).
The absence of any observed PCR product for M. bovis was expected, since the deletion of three plcencoding genes (plcA, plcB, and plcC ) in M. bovis (virulent strains and BCG strains) had already been reported by some authors. (21) Our PCR assay cannot differentiate M. tuberculosis from M. africanum, but both are susceptible to the same chemotherapeutic agents. Some authors (26) developed a PCR-based method to differentiate the subspecies of the M. tuberculosis complex on the basis of genomic deletions. Seven primer pairs were used in order to construct the M. tuberculosis complex PCR typing. However, the authors found that their method was unable to differentiate M. tuberculosis from M. africanum.
The PCR method described in the present study was also unable to differentiate between M. tuberculosis and M. africanum. However, we used only one pair of primers, and the interpretation of results was straightforward. Real-time PCR assays for the detection, differentiation, and quantitation of M. tuberculosis have recently been developed. (5) However, none of them can differentiate M. tuberculosis from M. africanum or from M. bovis.
The PCR results are in good agreement with the culture data, except for the 15 samples that were identified as negative in the PCR and positive in culture (out of 203 culture-positive samples) and the 2 samples that were identified as positive in the PCR and negative in culture (out of 55 culturenegative samples). In the case of the false-negatives, sensitivity might have been increased by the fact that more than one sample was collected from each patient. (10) In contrast, the false-positives might be attributable to the inclusion of paucibacillary patients presenting symptoms indicating infection with TB.
Within the M. tuberculosis complex, bacterial plc-encoding genes have been reported to play a role in the pathogenesis of many bacteria. Genetic 
Discussion
The rapid identification of M. tuberculosis is crucial to optimizing patient recovery. Species identification can take several weeks to complete, during which time the patient might receive inappropriate antimycobacterial agents. This is particularly worrisome if the patient is infected with M. bovis rather than M. tuberculosis, since M. bovis is resistant to pyrazinamide, a first-line antitubercular drug. (19) In the present study, we designed and tested the primers BC3 and BC5, which differentiate M. tuberculosis from M. bovis. The genomic fragment designated mtp40 has been tested as a species-specific DNA target for the identification of M. tuberculosis. (24) variations (IS6110 insertions and deletions) have been observed in the plcA-plcB-plcC and plcD regions. (27, 28) At M. tuberculosis plcC positions 19849 and 19668, (27) as well as 19589, 19645, and 19848, (29) IS6110 insertions have been observed. These findings indicate that this domain is a preferential integration region, defined as a <500-bp chromosomal domain. (27) One group of authors (30) reported that, in M. tuberculosis, there was a much 
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